Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment (2023)
- Authors:
- USP affiliated authors: TOLEDO, MONICA FRANCO ZANNINI JUNQUEIRA - FCF ; LOTUFO, LETICIA VERAS COSTA - ICB ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; PARISE FILHO, ROBERTO - FCF ; WAITMAN, KAROLINE DE BARROS - FCF ; ALMEIDA, LARISSA COSTA DE - ICB ; CARLOS, JORGE ANTONIO ELIAS GODOY - ICB
- Unidades: FCF; ICB
- Subjects: NEOPLASIAS; HIBRIDIZAÇÃO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher: Sociedade Brasileira de Química/SBQ
- Publisher place: São Paulo
- Date published: 2023
- Source:
- Título: Anais
- Conference titles: Reunião Anual da Sociedade Brasileira de Química/RASBQ
-
ABNT
WAITMAN, Karoline de Barros et al. Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment. 2023, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2023. Disponível em: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf. Acesso em: 27 dez. 2025. -
APA
Waitman, K. de B., Tavares, M. T., Almeida, L. C. de, Carlos, J. A. E. G., Kronenberger, T., Toledo, M. F. Z. J., et al. (2023). Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf -
NLM
Waitman K de B, Tavares MT, Almeida LC de, Carlos JAEG, Kronenberger T, Toledo MFZJ, Costa-Lotufo LV, Machado Neto JA, Parise Filho R. Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment [Internet]. Anais. 2023 ;[citado 2025 dez. 27 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf -
Vancouver
Waitman K de B, Tavares MT, Almeida LC de, Carlos JAEG, Kronenberger T, Toledo MFZJ, Costa-Lotufo LV, Machado Neto JA, Parise Filho R. Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment [Internet]. Anais. 2023 ;[citado 2025 dez. 27 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf - Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models
- Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents
- Compostos híbridos e usos dos referidos compostos
- Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models
- Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors
- Synthesis and biological evaluation of purine-benzohydroxamates as potential inhibitors of PI3K and HDAC6 for the treatment of hematologic malignancies
- AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy
- DNA damaging agents and DNA repair: from carcinogenesis to cancer therapy
- Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
3154883.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
